ALPS REIT Sector Dividend Dogs ETF (RDOG) News

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24...

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage...

Form 8-K/A - Current report: [Amend]

Savara to Present at the Jefferies Global Healthcare Conference

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management...

Form EFFECT - Notice of Effectiveness

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Savara’s Partner, Trillium Health LLC, Presented Data on the Laboratory Blood Test for Diagnosing aPAP Savara Inc. (Nasdaq: SVRA) (the Company...

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of...

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024 48-week placebo-controlled trial is evaluating...

Savara to Present at the Citizens JMP Life Sciences Conference

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management...

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on...

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]